TACSTD2 and renal cell carcinoma: The IMMU-132-01 trial evaluated the safety and efficacy of SG, a novel ADC consisting of anti-Trop-2, in patients with a variety of advanced epithelial cancers (including RCC) who developed disease progression after treatment with at least one standard regimen [46].